Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

redictive value, PPV) than patients in the Pegasys combination arm (92 vs. 87 vs. 80 percent, and 81 vs. 83 vs. 74 percent, respectively).(5)

-- Relapse after the end of treatment was lower for patients in the PEGINTRON combination therapy arms compared to patients receiving Pegasys and Copegus (24 vs. 20 vs. 32 percent, respectively). In a multivariate logistic regression analysis, among the factors significantly affecting relapse were: baseline viral load greater than 600,000 IU/mL vs. less than or equal to 600,000 IU/mL (p-value less than 0.001); age greater than 40 vs. less than or equal to 40 (p-value less than 0.001); fibrosis F3/4 vs. F0/1/2 (p-value equal to 0.001); Pegasys regimen vs. PEGINTRON 1.0 mcg regimen (p-value less than 0.001); glucose fasting greater than or equal to 5.6 vs. less than 5.6 (p-value equal to 0.002); steatosis 0 percent vs. greater than 0 percent (p-value equal to 0.002); ALT normal vs. elevated (p-value equal to 0.008); and Pegasys regimen vs. PEGINTRON 1.5 mcg regimen (p-value equal to 0.012).

-- End of treatment response was higher in the Pegasys combination arm (53 vs. 49 vs. 64 percent, respectively).

-- Ribavirin dose: One of the key questions of the study has been whether the protocol-assigned ribavirin dose regimen or the protocol-specified dose reduction schedule disadvantaged patients in any of the treatment arms, particularly in the Pegasys combination arm. However, the final results of IDEAL showed that the majority of patients in the Pegasys therapy arm received a higher ribavirin dose over the duration of the study, including patients with ribavirin dose reductions or discontinuations, based on the actual median ribavirin dose received (mg/kg/day), regardless of treatment outcome (SVR, relapsers and nonresponders) [p-value less than 0.001 for ribavirin dose received in the PEGINTRON 1.5 mcg arm vs. Pegasys arm and p-value less than or equal to 0.001 for ribavirin dose received in the PEGINTRON 1.0 a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Research and Markets ( ... "Surgical/Operating Microscopes Market by Application & End ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... poised to reach $806.6 million by 2020 from ... 12.3% from 2015 to 2020. , ,Major factors ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
(Date:5/29/2015)... 29, 2015 Educating the community continues ... for the Advancement of Wound Care (AAWC), which ... from AAWC,s corporate partners, the Association provides medical ... the AAWC website at http://aawconline.org/education-for-the-generalist/ . The ... with links to various CME/CEU educational programs. This ...
Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3The Association for the Advancement of Wound Care Educates the Public 2
... UBM Electronics leading brands, EE Times ... and Events Division of UBM Canon as a partner ... comprehensive program for designers, developers, and engineering managers involved ... conference and exposition is being held February 8-10, 2011, ...
... RetireSafe, a 400,000-supporter strong national advocacy group for ... & Coverage Advisory Committee (MEDCAC) to support the ... new Provenge treatment procedure for prostate cancer patients. ... "consider not only the many Americans suffering from ...
Cached Medicine Technology:UBM Electronics' EE Times and EDN Partner with Medical Electronics Design, MD+DI, and Others on DesignMED Event for Designers of Medical Electronics Devices 2UBM Electronics' EE Times and EDN Partner with Medical Electronics Design, MD+DI, and Others on DesignMED Event for Designers of Medical Electronics Devices 3RetireSafe Urges Support for Provenge Prostate Cancer Treatment 2
(Date:5/29/2015)... Healthpointe clinics throughout Southern California are ... of their licensed clinical psychologist, Dr. Levon Margolin. ... to an extensive array of physical, cognitive, emotional, and ... any time after a traumatic ordeal involving the brain. ... or jolt to the head that impedes the normal ...
(Date:5/29/2015)... Texas (PRWEB) May 29, 2015 ... the current state of the Naproxen industry.The report ... definitions, classifications, applications and industry chain structure. The ... the international markets including development trends, competitive landscape ... plans are discussed as well as manufacturing processes ...
(Date:5/29/2015)... The popular all-natural supplement brand, ... L-Style Select Program that gives bonuses to members for ... only 100 members per year, lucky members who are ... with fitness experts at Nuretix Research, and get exclusive ... that they attain and maintain their weight loss and ...
(Date:5/29/2015)... Recently, renowned facelift specialist , Dr. Rod ... the 46th National Congress of Plastic Aesthetic and Reconstructive ... Rohrich, a Dallas plastic surgeon who serves ... UT Southwestern Medical Center, discussed the implications of the ... obtaining long term results. , Based on a number ...
(Date:5/29/2015)... Texas (PRWEB) May 29, 2015 Testosterone Centers ... the DFW area, is opening a new center in the ... the rest of the Mid Cities. Located on the south ... Road in Hurst, the new testosterone center will open in ... women who suffer from low testosterone. , Like TCT’s other ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:Dr. Rod J. Rohrich Speaks on Longevity in Facelifts and Facial Rejuvenation 2Health News:Dr. Rod J. Rohrich Speaks on Longevity in Facelifts and Facial Rejuvenation 3Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
... ... into the holiday spirit and is virtually giving away a very popular marketing tool. ... is even including chiropractic promotional templates free of cost. , ... (PRWEB) December 3, 2009 -- Chiropractic ...
... SOUTHBRIDGE, Mass., Dec. 3 The Cancer Center ... Harrington Hospital announced today. , "We expect to start seeing ... at Harrington. , The approval was granted today by the ... review of the facility. , The opening of The ...
... , WASHINGTON, Dec. 3 ... the Senate health care bill by a vote of 61-39. ... it also fails to explicitly exclude it. ... as "preventive care," and would therefore recommend coverage for abortion ...
... , BEVERLY HILLS, Calif., Dec. 3 ... Design Gala and Premier Shopping Event for Project Angel Food, ... The event kicks off on Thursday, December 3 and ... Boulevard (formerly Robinsons May), Beverly Hills, California. Please visit ...
... continues for 12 weeks and includes minimally invasive procedures, study ... blood clots after surgery are a much greater risk than ... is most striking is that not only is the risk ... thought," said Dr. Jane Green, a clinical epidemiologist at the ...
... school and home, study finds , THURSDAY, Dec. 3 (HealthDay News) ... sisters at home, according to an Italian study that included 195 ... -- all with a sibling no more than four years older ... were bullied at school or at home. The findings were published ...
Cached Medicine News:Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Americans United For Life: Senate Passes the Pro-Abortion Mikulski Amendment Under the Guise of 'Preventive Care' 2Health News:Christian Audigier Represented at Divine Design for Project Angel Food 2Health News:Blood Clot Threat After Surgery Worse Than Thought 2Health News:Blood Clot Threat After Surgery Worse Than Thought 3Health News:Bullies May Intimidate Siblings, Too 2
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Medicine Products: